Evidence map›Paper›PMID 41555397›Full record

ArticleCardio-oncology (London, England)2026

Statin initiation among cancer survivors with asymptomatic coronary atherosclerosis.

Cheng Hwee Soh, Shristy Shrestha, Kristyn Whitmore, Batsheva Greenbaum, Atro Azad, Melinda J Carrington, Joel Smith, Thomas H Marwick

Abstract read
In one paragraph

Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cheng Hwee SohImaging Research Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Shristy ShresthaImaging Research Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Kristyn WhitmoreBaker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia.
Batsheva GreenbaumCommunity Prevention and Cardiac Research, Baker Heart and Diabetes Institute, Melbourne, Australia.
Atro AzadImaging Research Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Melinda J CarringtonBaker Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Melbourne, Australia.
Joel SmithImaging Research Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Thomas H MarwickImaging Research Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia. tom.marwick@baker.edu.au.

Funding

National Health and Medical Research Council 2008129
6 · The paper itself

Abstract

backgroundCancer survivors are at higher risk of developing heart disease, but it is unclear whether they receive adequate preventive care. This study aimed to compare the statin initiation rates between cancer survivors and non-cancer controls.

methodsCancer survivors and similar statin-naïve controls were recruited from the community. Intermediate risk participants, based on their conventional cardiovascular risk factors, were referred for coronary artery calcium score (CACS). This result was relayed to participants’ primary care provider (PCP), who determined therapy. Multivariable logistic regression models were constructed to identify the associations between cancer history and statin initiation by PCP.

resultsThis study compared management of 97 cancer survivors (median age 67 [64–70] years, 84.5% female) and 109 non-cancer controls (median age 64 [60–67] years, 36.7% female). The median CACS for survivors and controls were 62 [16–124] and 144 [28–554] followed by the overall statin prescription rates of 54% and 69%, respectively. Multivariable logistic regression showed that cancer history was not associated with statin initiation by PCP after adjustment for CACS, age, sex and other cardiovascular risk factors.

conclusionStatin prescribing by primary care providers was generally aligned with guideline recommendations and did not differ substantially by cancer history. However, many individuals with any detectable coronary calcium (CACS > 0) remained untreated, despite this being a clear marker of elevated risk of atherosclerotic cardiovascular disease. These findings suggest that undertreatment may not be driven by clinical inertia alone, underscoring the need to explore alternative barriers to preventive care in this vulnerable population.

Indexed as

AtherosclerosisCancer survivorsStatin

Identifiers

PMID41555397
PMCPMC12895647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.